ESR1 and breast carcinoma: Interestingly, data presented by Rhiem et al. (2012) and by the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database, found that incidence of contralateral breast cancer after 10 years in familial non-BRCA1/2 PV carriers was similar to sporadic breast cancer (contralateral breast cancer risk of 2.5% to 12.6% in 10 years depending on estrogen-receptor status and age of onset) [18].